source
- FDA staff raise concerns over Replimune's skin cancer drug dataFDA staff have reiterated concerns that Replimune's investigational skin cancer therapy lacks sufficient data for approval. The agency highlighted the single-arm trial, in which patients previousl…
- ProMIS Neurosciences early trial shows low brain bleeding and no swelling, hinting at safer Alzheimer’s drugProMIS Neurosciences reported interim safety data from a early‑stage trial of its amyloid‑targeting therapy for Alzheimer’s disease. The analysis pooled data from participants receiving the investi…